New Therapeutic and Biomarker Discovery for Peripheral Diabetic Neuropathy: PARP Inhibitor, Nitrotyrosine, and Tumor Necrosis Factor-α
Open Access
- 31 March 2010
- journal article
- other
- Published by The Endocrine Society in Endocrinology
- Vol. 151 (6) , 2547-2555
Abstract
This study evaluated poly(ADP-ribose) polymerase (PARP) inhibition as a new therapeutic approach for peripheral diabetic neuropathy using clinically relevant animal model and endpoints, and nitrotyrosine (NT), TNF-α, and nitrite/nitrate as potential biomarkers of the disease. Control and streptozotocin-diabetic rats were maintained with or without treatment with orally active PARP inhibitor 10-(4-methyl-piperazin-1-ylmethyl)-2H-7-oxa-1,2-diaza-benzo[de]anthracen-3-one (GPI-15,427), 30 mg kg−1 d−1, for 10 wk after first 2 wk without treatment. Therapeutic efficacy was evaluated by poly(ADP-ribosyl)ated protein expression (Western blot analysis), motor and sensory nerve conduction velocities, and tibial nerve morphometry. Sciatic nerve and spinal cord NT, TNF-α, and nitrite/nitrate concentrations were measured by ELISA. NT localization in peripheral nervous system was evaluated by double-label fluorescent immunohistochemistry. A PARP inhibitor treatment counteracted diabetes-induced motor and sensory nerve conduction slowing, axonal atrophy of large myelinated fibers, and increase in sciatic nerve and spinal cord NT and TNF-α concentrations. Sciatic nerve NT and TNF-α concentrations inversely correlated with motor and sensory nerve conduction velocities and myelin thickness, whereas nitrite/nitrate concentrations were indistinguishable between control and diabetic groups. NT accumulation was identified in endothelial and Schwann cells of the peripheral nerve, neurons, astrocytes, and oligodendrocytes of the spinal cord, and neurons and glial cells of the dorsal root ganglia. The findings identify PARP as a compelling drug target for prevention and treatment of both functional and structural manifestations of peripheral diabetic neuropathy and provide rationale for detailed evaluation of NT and TNF-α as potential biomarkers of its presence, severity, and progression.Keywords
This publication has 68 references indexed in Scilit:
- Poly(Adenosine 5′-Diphosphate-Ribose) Polymerase Inhibition Counteracts Multiple Manifestations of Experimental Type 1 Diabetic NephropathyEndocrinology, 2009
- Microvascular Reactivity and Inflammatory Cytokines in Painful and Painless Peripheral Diabetic NeuropathyThe Journal of Clinical Endocrinology & Metabolism, 2009
- Intranasal Insulin Ameliorates Experimental Diabetic NeuropathyDiabetes, 2009
- Inducible nitric oxide synthase gene deficiency counteracts multiple manifestations of peripheral neuropathy in a streptozotocin-induced mouse model of diabetesDiabetologia, 2008
- Nitrosylated Proteins in Monocytes as a new Marker of Oxidative-Nitrosative Stress in Diabetic Subjects with MacroangiopathyExperimental and Clinical Endocrinology & Diabetes, 2008
- PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathyFree Radical Biology and Medicine, 2008
- Nitric Oxide and Peroxynitrite in Health and DiseasePhysiological Reviews, 2007
- Poly(ADP-ribose) (PAR) polymer is a death signalProceedings of the National Academy of Sciences, 2006
- Poly(ADP-Ribose) Polymerase Inhibition Alleviates Experimental Diabetic Sensory NeuropathyDiabetes, 2006
- Aldose reductase inhibition counteracts nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic rat kidney and high-glucose-exposed human mesangial cellsFree Radical Biology and Medicine, 2006